# Genome-wide meta-analysis of quantitatively measured generalized anxiety symptoms in individuals of European ancestry.

- **DOI:** [10.1038/s41562-026-02476-7](https://doi.org/10.1038/s41562-026-02476-7)
- **Rating:** Strong (4.0 out of 5)
- **Verdict:** The largest quantitative anxiety GWAS to date delivers 74 loci and cross-ancestry polygenic signal, but its loci largely index broader neuroticism-related liability.
- **Framework version:** v5.9
- **Pipeline version:** v0.4
- **Evaluation date:** 2026-10-08
- **Evaluation page:** https://www.nabu.science/paper/10.1038%2Fs41562-026-02476-7

## Key claims

1. We identified 80 independent genome-wide significant variants within 74 loci, 39 of which were newly associated with anxiety.
   - Support: Well-supported
   - Type: Primary finding
   - Basis: Well-powered meta-analysis of 693,869 individuals with standardized QC; novelty defined strictly against catalogued internalizing-trait associations
   - Location: Abstract; Results, Genome-wide association meta-analysis
2. SNP-based heritability was 5.9% (posterior s.d. = 0.15%).
   - Support: Well-supported
   - Type: Secondary
   - Basis: SBayesRC estimate with tight posterior SD, consistent with a prior quantitative anxiety estimate and discussed against liability-scale values
   - Location: Abstract; Results, SNP-based heritability and genetic correlations with external traits
3. Polygenic scores were significantly associated with anxiety symptom severity and disorder in European, African and South Asian ancestry samples (R2 = 1.2-2.9%).
   - Support: Supported
   - Type: Secondary
   - Basis: Target samples of 1,303-3,452 drawn partly from a discovery cohort with overlap handling unstated; variance explained is small
   - Location: Abstract; Results, Polygenic risk scores
4. Significant genetic correlations (rg) were estimated with mental and physical health traits, including case-control anxiety, neuroticism and depression (rg = 0.71-0.85), irritable bowel syndrome (rg = 0.57), coronary artery disease, endometriosis and migraine (rg = 0.20-0.27).
   - Support: Supported
   - Type: Secondary
   - Basis: Bonferroni-corrected LD score regression across 105 traits; correlations are associative and need not reflect horizontal pleiotropy
   - Location: Abstract; Results, SNP-based heritability and genetic correlations with external traits
5. These findings highlight the discovery power gained from analysing a quantitative trait rather than a case-control phenotype in anxiety genetics.
   - Support: Tentative
   - Type: Secondary
   - Basis: Locus-count comparison against a largely overlapping, differently composed case-control study is not a controlled contrast
   - Location: Abstract, final sentence; Discussion, final paragraph

## Strengths

- **Scale and consistency of the discovery analysis** Meta-analysis of 693,869 individuals across 14 cohorts in 8 countries yields 80 independent genome-wide significant variants within 74 loci. Median I² for the LD-independent lead SNPs is 0%, and cross-cohort genetic correlations range from 0.64 to 0.97, indicating consistent effect estimates despite differing instruments.
  - Dimension: methodological rigour
  - Location: Results, Genome-wide association meta-analysis; Supplementary Tables 4 and 7
- **Conditional analyses reported with their own caveats** mtCOJO conditioning on neuroticism, case-control anxiety and depression is reported in full, including that only two loci survive conditioning on neuroticism, alongside standard-error inflation of 7-9% and sign changes in 17-20% of variants as evidence of instability. The Discussion draws the implication that many loci may index broader neuroticism-related liability.
  - Dimension: methodological rigour
  - Location: Results, Conditional analyses; Discussion, paragraph 4
- **Advance delineated against the closest prior study** The paper reports that all 58 loci from the prior case-control anxiety GWAS show the same direction of effect here, with 19 reaching genome-wide significance, and names the five non-overlapping cohorts and approximate added sample. This makes the increment over prior work auditable rather than asserted.
  - Dimension: contribution
  - Location: Results, Genome-wide association meta-analysis; Methods, Meta-analysis
- **Limitations carried into interpretation** The European-ancestry restriction, the GAD-7's incomplete DSM-5 symptom coverage, measurement noise from recent-symptom scales, and the underpowered subgroup comparisons are each connected to a specific consequence for what can be concluded. The paper states it cannot be certain all cohorts captured the same underlying genetic architecture.
  - Dimension: positioning
  - Location: Discussion, paragraphs 3-5

## Limitations

- **Power comparison against case-control is uncontrolled** The claim that quantitative phenotyping delivers superior discovery rests on comparing 74 loci here with 58 loci from a larger case-control study, but nine of the 14 cohorts overlap that study and sample composition differs by the availability of symptom versus diagnostic data. The comparison is suggestive rather than an identified contrast.
  - Dimension: contribution
  - Location: Abstract, final sentence; Discussion, final paragraph; Methods, Meta-analysis
- **Subgroup equivalence checks are underpowered** Cohorts used six different symptom measures and mixed community and clinical ascertainment, but the paper reports that most pairwise cohort and subgroup genetic-correlation comparisons had heritability z-scores below 4. Equivalence of genetic architecture across instruments is therefore not established, only not contradicted.
  - Dimension: methodological rigour
  - Location: Results, Genome-wide association meta-analysis; Methods, Meta-analysis
- **Polygenic score validation rests on small samples** Target samples number 1,303 to 3,452 individuals with 218 to 407 cases, drawn partly from UK Biobank, which also contributes to discovery; how overlap was excluded is not described. The liability-scale conversion assumes 20% population prevalence against observed case fractions nearer 13-17%.
  - Dimension: methodological rigour
  - Location: Methods, PRSs; Results, Polygenic risk scores
- **Discovery restricted to European ancestry** All 14 discovery cohorts are European-ancestry, and cross-ancestry polygenic scores explain only 1.2-1.4% of variance in African and South Asian samples versus 2.9% in European. Population-specific risk loci cannot be identified from this design.
  - Dimension: application pathway
  - Location: Abstract; Results, Polygenic risk scores; Discussion, paragraph 5

## Reliability checks

Caveats (4 of 4 checks).

- **Results check:** Clean. The reported numbers and statistics are consistent with the stated results.
- **Reporting and transparency:** Noted. The gene-based locus label differs from the primary GWAS count, and the text does not explain how UK Biobank discovery and PRS target participants were kept independent.
  - Ethics approval: declared · Preregistration: not stated · Data availability: declared · Code availability: not stated
- **Reference integrity:** Clean
  - 95 references in manuscript
  - 95 of 95 checkable references found in an index
  - 6 references confirmed by manual review
  - References not verified automatically are resolved manually within 24 hours.

## Post-publication record

- **Status:** Clean
- **Summary:** No retraction or expression of concern found in Crossref (includes Retraction Watch).
- **Last checked:** 2026-10-17
